Pregled bibliografske jedinice broj: 212259
Dizajniranje i primjena prolijekova
Dizajniranje i primjena prolijekova // Knjiga sažetaka, Treći hrvatski kongres farmacije s međunarodnim sudjelovanjem / Zorc, Branka (ur.).
Zagreb: Farmaceutsko-biokemijski fakultet Sveučilišta u Zagrebu, 2005. str. 30-30 (pozvano predavanje, domaća recenzija, sažetak, pregledni)
CROSBI ID: 212259 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Dizajniranje i primjena prolijekova
(Design and Application of Prodrugs)
Autori
Jadrijević-Mladar Takač, Milena ; Branka, Zorc
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, pregledni
Izvornik
Knjiga sažetaka, Treći hrvatski kongres farmacije s međunarodnim sudjelovanjem
/ Zorc, Branka - Zagreb : Farmaceutsko-biokemijski fakultet Sveučilišta u Zagrebu, 2005, 30-30
Skup
Treći hrvatski kongres farmacije s međunarodnim sudjelovanjem
Mjesto i datum
Cavtat, Hrvatska, 27.04.2005. - 30.04.2005
Vrsta sudjelovanja
Pozvano predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
Prodrug design; Drug; Prodrug; Drug rational design; Prodrug approach
Sažetak
Prodrug design comprises an area of drug research, which is concerned with the optimization of drug delivery. A prodrug is pharmacologically inactive derivative of a parent molecule, which requires spontaneous, i.e. non-enzymatic, or enzymatic transformation within the body in order to release the active drug. A prodrug has improved delivery properties over the parent drug molecule. A molecule with optimal structural configuration and physico-chemical properties for eliciting the desired therapeutic response at its target site, does not necessarily posses the best molecular form and properties for its delivery to its site of ultimate action. Prodrugs are designed to overcome pharmaceutically and/or pharmacokinetically based problems associated with the parent drug molecule, which otherwise would be of limited clinical use. In the pharmacokinetic phase, i.e. the absorption, distribution, metabolism and excretion of the drug, major barriers, which may limit the usefulness of a drug, are: incomplete absorption of the drug across biological membranes (GI mucosa or the blood-brain barrier), incomplete systemic bioavailability of a drug due to presystemic metabolism, too rapid absorption or excretion of the drug when a longer duration of action is desired, toxicity problems, poor site-specificity of the drug. The rational design of prodrugs can be divided into three basic steps: - identification of the drug delivery problem, - identification of the physico-chemical properties required for maximum efficacy or delivery, and - selection of a prodrug derivative which has the proper physico-chemical properties and which can be cleaved in the desired biological compartment. The prodrug approach has been successfully applied to a wide variety of drugs. Most of the applications have involved enhancement of bioavailability and passage through various biological barriers, increased duration of pharmacological effects, increased site-specificity, decreased toxicity and adverse reactions, improvement of organoleptic properties and improvement of stability and solubility properties.
Izvorni jezik
Engleski
Znanstvena područja
Farmacija
POVEZANOST RADA
Projekti:
0006543
Ustanove:
Farmaceutsko-biokemijski fakultet, Zagreb
Profili:
Milena Jadrijević-Mladar Takač
(autor)